Immunotherapy improves responses w/o reducing quality of life in early breast cancer

(Dana-Farber Cancer Institute) Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news